Reqorsa
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Reqorsa, covering 2025-02-20 to 2026-01-21. Get the full timeline:
Most recent: Clinical Trial Update: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib [Phase 1, Phase 2]